This 2005 report examines the issues surrounding the tenofovir trials and makes recommendations for ensuring that trials are carried out ethically and that provisions are made for dealing with the results of the trials when they are available. The report also calls for more concerted coordination and advance planning to accelerate evaluation, licensing, and access to PrEP.
Will a pill a day prevent HIV? Anticipating the results of the tenofovir “PrEP” trials
Understanding the Results of the AIDSVAX Trial
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Understanding the Results of the AIDSVAX Trial (French)
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Understanding the Results of the AIDSVAX Trial (Spanish)
In late February 2003, the world heard preliminary results of the first large-scale human trial of a vaccine designed to prevent HIV infection. The results for the overall trial cohort were clear and disappointing. The results for a relatively small subset of trial participants are less clear, and they have sparked controversy and require further analysis. This brochure will help you understand what we do and do not know about the experimental vaccine known as AIDSVAX.
Ongoing and Planned PrEP Demonstration and Implementation Studies
This is a summary table of ongoing and planned global PrEP evaluation studies.
Ready, Set, Rectal Microbicides: An Update on Rectal Microbicide Research and Advocacy
Until recently, microbicide research has focused on vaginal microbicides. Recent initiatives and ongoing studies highlight the need for safe and effective rectal microbicides as part of an essential HIV prevention toolkit.
Community-driven strategies for the use of antiretrovirals as prevention: United States Workshop Report
Launched in 2011, the multi-national Mapping Pathways project provides a community-led, research-driven, multi-layered synthesis about the use of antiretroviral-based prevention strategies. Project partners included RAND, AIDS Foundation of Chicago, AIDS United, Desmond Tutu HIV Foundation, Naz India, and Bairds CMC.
In the latter half of 2013, a subset of the Mapping Pathways team from RAND Europe and AIDS Foundation of Chicago conducted a series of three “knowledge exchange” scenario development workshops with a focus on the United States, held in San Francisco, California; Atlanta, Georgia; and Washington, DC. The aim of the workshops was to further share the findings of the report and to continue enhancing the community-driven, locally informed approach to the wider evidence base for ARV-based prevention. This report summarizes the outputs of those three workshops.
Mapping Pathways: Developing evidence-based, people-centred strategies for the use of antiretrovirals as prevention
Mapping Pathways is a multinational project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral (ARV)-based prevention strategies to end the HIV/AIDS epidemic. The project is based on the premise that the current array of prevention options is not sufficient; new pathways to prevention, based on enhanced assessment and analysis of likely impact, are needed to address new infections adequately.
Voluntary Medical Male Circumcision: What Gets Counted
This table from Px Wire January-March 2014 Volume 7, No.1 examines why the global systems for tracking voluntary medical male circumcision are lagging behind the actual progress being made.
AIDS Vaccine Science for Busy Advocates – Current AIDS Vaccine R&D Pipeline
One-pager reviewing what we’ve learned from previous efficacy trials, the product pipeline and where we are today and future directions toward finding a vaccine that works.